Tumors of the central nervous system among women treated with fertility drugs: a population-based cohort study.
Central nervous system neoplasms
Cohort studies
Fertility agents
Glioma
Infertility
Meningioma
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
21
04
2022
accepted:
29
06
2022
pubmed:
28
7
2022
medline:
2
9
2022
entrez:
27
7
2022
Statut:
ppublish
Résumé
To investigate the association between fertility drugs and tumors of the central nervous system (CNS). This cohort study was based on The Danish Infertility Cohort and included 148,016 infertile women living in Denmark (1995-2017). The study cohort was linked to national registers to obtain information on use of specific fertility drugs, cancer diagnoses, covariates, emigration, and vital status. Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for all CNS tumors and separately for gliomas, meningiomas and diverse benign tumors of the brain and other parts of the CNS. During a median 11.3 years of follow-up, 328 women were diagnosed with CNS tumors. No marked associations were observed between use of the fertility drugs clomiphene citrate, gonadotropins, gonadotropin-releasing hormone receptor modulators and progesterone and CNS tumors. However, use of human chorionic gonadotropin was associated with a decreased rate of meningiomas (HR 0.49 95% CI 0.28-0.87). No clear associations with CNS tumors were observed according to time since first use or cumulative dose for any of the fertility drugs. No associations between use of most types of fertility drugs and CNS tumors were observed. However, our findings only apply to premenopausal women and additional studies with longer follow-up time are necessary.
Identifiants
pubmed: 35895242
doi: 10.1007/s10552-022-01610-w
pii: 10.1007/s10552-022-01610-w
doi:
Substances chimiques
Fertility Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285-1293Subventions
Organisme : Kræftens Bekæmpelse
ID : internal grant
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
GBD Brain and Other CNS Cancer Collaborators (2019) Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(4):376–393
doi: 10.1016/S1474-4422(18)30468-X
Hirtz A, Rech F, Dubois-Pot-Schneider HA-O, Dumond HA-O (2020) Astrocytoma: a hormone-sensitive tumor? Int J Mol Sci 21(23):9114
doi: 10.3390/ijms21239114
Ogasawara C, Philbrick BD, Adamson DC (2021) Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines 9(3):319
doi: 10.3390/biomedicines9030319
Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schuz J (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst 101(24):1721–1724
doi: 10.1093/jnci/djp415
McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, Menck HR, Laws ER Jr (1998) Factors associated with survival in patients with meningioma. J Neurosurg 88(5):831–839
doi: 10.3171/jns.1998.88.5.0831
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4(4):278–299
doi: 10.1093/neuonc/4.4.278
Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, Aldape KD (2005) The molecular epidemiology of gliomas in adults. Neurosurg Focus 19(5):E5
doi: 10.3171/foc.2005.19.5.6
Chen C, Xu T, Chen J, Zhou J, Yan Y, Lu Y, Wu S (2011) Allergy and risk of glioma: a meta-analysis. Eur J Neurol 18(3):387–395
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncology 22(12 Suppl 2):iv1–iv96
doi: 10.1093/neuonc/noaa200
McKinley BP, Michalek AM, Fenstermaker RA, Plunkett RJ (2000) The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J Neurosurg 93(6):932–939
doi: 10.3171/jns.2000.93.6.0932
Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-Oncol 99(3):307–314
doi: 10.1007/s11060-010-0386-3
Benson VS, Kirichek O, Beral V, Green J (2015) Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 136(10):2369–2377
doi: 10.1002/ijc.29274
Lan YL, Wang X, Lou JC, Ma BB, Xing JS, Zou S, Zhang B (2018) Update on the effect of exogenous hormone use on glioma risk in women: a meta-analysis of case–control and cohort studies. J Neuro-Oncol 137(2):357–365
doi: 10.1007/s11060-017-2725-0
Momenimovahed Z, Taheri S, Tiznobaik A, Salehiniya H (2019) Do the fertility drugs increase the risk of cancer? A review study. Front Endocrinol (Lausanne) 10:313
doi: 10.3389/fendo.2019.00313
Wigertz A, Lonn S, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ et al (2008) Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 17(10):2663–2670
doi: 10.1158/1055-9965.EPI-08-0406
Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Brinton LA, Storeng R (2015) Cancer risk among parous women following assisted reproductive technology. Hum Reprod 30(8):1952–1963
doi: 10.1093/humrep/dev124
Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO (2011) Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 26(1):253–258
doi: 10.1093/humrep/deq307
Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E (2012) Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod 27(4):1149–1155
doi: 10.1093/humrep/des031
Reigstad MM, Storeng R, Myklebust TA, Oldereid NB, Omland AK, Robsahm TE, Brinton LA, Vangen S, Furu K, Larsen IK (2017) Cancer risk in women treated with fertility drugs according to parity status—a registry-based cohort study. Cancer Epidemiol Biomarkers Prev 26(6):953–962
doi: 10.1158/1055-9965.EPI-16-0809
Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A (2010) Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland. Cancer Causes Control 21(12):2149–2156
doi: 10.1007/s10552-010-9634-2
Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM (2013) Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 118(3):649–656
doi: 10.3171/2012.9.JNS12811
Kjaer SK, Sharif HF, Olsen JH, Bock JE (1999) The Danish Infertility Cohort—a research database. Ugeskr Laeger 161(47):6503–6504
pubmed: 10778360
WHO Collaborating Centre for Drug Statistics Methodology (2021) Guidelines for ATC classification and DDD assignment 2021. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, p 20
Frassanito P, De Bonis P, Mattogno PP, Novello M, Anile C (2012) Hormonal therapy for fertility and huge meningioma: a purely random association? Acta Neurol Belg 112(3):299–301
doi: 10.1007/s13760-012-0046-9
Motegi H, Kobayashi H, Terasaka S, Ishii N, Ito M, Shimbo D, Kubota K, Houkin K (2012) Hemorrhagic onset of rhabdoid meningioma after initiating treatment for infertility. Brain Tumor Pathol 29(4):240–244
doi: 10.1007/s10014-012-0088-y
Patterson AA-O, Elashaal A (2016) Fast-growing meningioma in a woman undergoing fertility treatments. Case Rep Neurol Med. https://doi.org/10.1155/2016/3287381
doi: 10.1155/2016/3287381
pubmed: 28116188
pmcid: 5220424
Shy H, Malaiyandi L, Timiras PS (2000) Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 18(2–3):289–297
doi: 10.1016/S0736-5748(99)00097-0
Carroll RS, Zhang J, Dashner K, Sar M, Black PM (1995) Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 37(3):496–503 (discussion 503–494)
doi: 10.1227/00006123-199509000-00019
Ezcurra D, Humaidan P (2014) A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology. Reprod Biol Endocrinol 12:95–95
doi: 10.1186/1477-7827-12-95
Sanson M, Cornu P (2000) Biology of meningiomas. Acta Neurochir (Wien) 142(5):493–505
doi: 10.1007/s007010050462
Peyre M, Gaillard S, de Marcellus C, Giry M, Bielle F, Villa C, Boch AL, Loiseau H, Baussart B, Cazabat L et al (2018) Progestin-associated shift of meningioma mutational landscape. Ann Oncol 29(3):681–686
doi: 10.1093/annonc/mdx763
Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH (2000) Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 65(10–11):795–800
doi: 10.1016/S0039-128X(00)00193-8
Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE (2011) Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study. Int J Cancer 128(4):944–950
doi: 10.1002/ijc.25413
Michaud DS, Bove G, Gallo V, Schlehofer B, Tjonneland A, Olsen A, Overvad K, Dahm CC, Teucher B, Boeing H et al (2011) Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 4(9):1385–1392
doi: 10.1158/1940-6207.CAPR-11-0014
Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2013) Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer 109(1):289–294
doi: 10.1038/bjc.2013.304
Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 99(1):185–190
doi: 10.1038/sj.bjc.6604445